Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study

Multiple sclerosis (MS) patients receiving natalizumab and who are at risk of developing progressive multifocal leukoencephalopathy (PML) often switch to other high-efficacy disease-modifying therapies including fingolimod as a risk mitigation strategy, which could impact treatment safety and effect...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Helmut Butzkueven, Paul S. Giacomini, Stanley Cohan, Tjalf Ziemssen, Daniel Sienkiewicz, Ying Zhang, Yvonne Geissbühler, Diego Silva, Davorka Tomic, Harald Kropshofer, Maria Trojano
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	MDPI AG 2022-02-01
سلاسل:	Brain Sciences
الموضوعات:	fingolimod natalizumab switching transition observational study
الوصول للمادة أونلاين:	https://www.mdpi.com/2076-3425/12/2/215
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!